World Workshop on Oral Medicine VII:Immunobiologics for Salivary Gland Disease in Sjögren’s Syndrome: A Systematic Review by Alcino Gueiros, Luiz et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1111/odi.13062
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Alcino Gueiros, L., France, K., Posey, R., Mays , J. W., Carey, B., Sollecito, T. P., ... De Rossi, S. (2019). World
Workshop on Oral Medicine VII: Immunobiologics for Salivary Gland Disease in Sjögren’s Syndrome: A
Systematic Review. Oral Diseases, 25(S1), 102-110. https://doi.org/10.1111/odi.13062
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 10. Jul. 2020
  1 
Title 
WWOM VII: Immunobiologics for Salivary Gland Disease in Sjögren’s Syndrome: A 
Systematic Review  
 
Running title 
WWOM VII: Immunobiologics in Sjogren’s Syndrome 
 
Keywords: 
Sjogren’s Syndrome, biologic agents, xerostomia, salivary flow 
 
Luiz Alcino Gueiros, DDS, MSc, PhD,1 Katherine France, DMD, MBE,2 Rachael Posey, 
MSLS,3 Jacqueline W. Mays DDS, MHSc, PhD,4 Barbara Carey, MB, BDS,5 Thomas P. 
Sollecito, DMD, FDS RCSEd,2 Jane Setterfield, BDS, DCH, MD, FRCP,5 Sook Bin Woo, 
DMD, MMSc, FDS RCSEd,6 Donna Culton, MD, PhD,7 Aimee S. Payne, MD, PhD,8 
Giovanni Lodi, DDS, PhD,9 Martin S. Greenberg, DDS, FDS RCSEd,2 Scott De Rossi, 
DMD, MBA10 
 
1 – Oral Medicine Unit. Department of Clinic and Preventive Dentistry, Universidade 
Federal de Pernambuco, Recife, Brazil 
2 – Department of Oral Medicine, University of Pennsylvania School of Dental Medicine, 
Philadelphia, PA, USA 
3 – William Rand Kenan, Jr. Library of Veterinary Medicine, North Carolina State 
University, Raleigh, NC, USA 
4 – Oral Immunobiology Unit, National Institute of Dental and Craniofacial Research, 
National Institutes of Health, Bethesda, MD, USA 
5 – Department of Oral Medicine, Guy's and St Thomas' NHS Foundation Trust, London, 
UK 
6 – Department of Oral Medicine, Infection, and Immunity. Harvard School of Dental 
Medicine, Boston, MA, USA 
7 – Department of Dermatology, University of North Carolina at Chapel Hill, Chapel 
Hill, NC, USA 
8 – Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA 
9 – Oral Medicine Unit, Dipartimento di Scienze Biomediche, Chirurgiche e 
Odontoiatriche, Università degli Studi di Milano, Milan, Italy 
10 –School of Dentistry, The University of North Carolina at Chapel Hill, Chapel Hill, 
NC, USA 
 
Corresponding Author: 
 
Prof. Luiz Alcino Gueiros, DDS, MSc, PhD  
Oral Medicine Unit. Department of Clinic and Preventive Dentistry 
Universidade Federal de Pernambuco 
Av. Prof. Moraes Rego, 1235, CDU 
Recife – PE, Brazil. CEP: 50.670-901 
luiz.mgueiros@ufpe.br  
Fax: +55 81 2126.8817 
 
Date of Submission 
January 20th, 2019 
  
  2 
ABSTRACT 
 
Objective. This systematic review evaluated the efficacy of immunobiologics for 
management of oral disease in Sjögren’s syndrome.  
Materials and Methods. MEDLINE®, Embase, Scopus and the Cochrane Library were 
searched for evidence on the use of immunobiologics for management of glandular 
disease in Sjögren’s syndrome. Primary outcomes were xerostomia and salivary gland 
dysfunction, assessed via visual analogue scales, disease-specific scales for Sjögren’s 
syndrome, measurement of salivary flow, ultrasound data, and quality of life measures.  
Results. Seventeen studies (11 randomized controlled trials and 6 observational studies) 
met inclusion criteria. Rituximab showed efficacy in improving salivary gland function 
but not xerostomia. Abatacept showed promise in improving both xerostomia and 
salivary flow. Belimumab exhibited long term improvement of salivary flow and 
subjective measures. The novel agent CFZ533 improved both disease activity and patient-
reported indexes. 
Conclusions. There is strong evidence pointing to the efficacy of rituximab in the 
management of oral disease in Sjögren’s syndrome. Future controlled trials may elucidate 
the efficacy of belimumab and abatacept.  The new drug CFZ533 is a promising 
alternative for the management of Sjögren’s syndrome and its salivary gland 
involvement. In considering these agents, the promise of efficacy must be balanced 
against the harmful effects associated with biologic agents. 
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1. INTRODUCTION 
Sjögren’s syndrome (SS) is an autoimmune disease affecting approximately 3.1 
million patients in the United States of America (Carsons et al., 2017). The disease is 
chronic and often slowly progressive. Early impact occurs in the secretory glands, 
predominantly the salivary and lacrimal glands. However, SS can also affect the joints, 
gastrointestinal tract, central nervous system, and other organs, and has been linked to an 
increased risk for lymphoma (Alunno, Leone, Giacomelli, Gerli & Carubbi, 2018). The 
majority of affected patients are diagnosed with SS in the absence of other autoimmune 
conditions (primary SS - pSS). Some patients, however, may develop secondary SS (sSS) 
as a sequel of rheumatological conditions including systemic lupus erythematosus and 
rheumatoid arthritis (Georgakopoulou, Andreadis, Arvanitidis, & Loumou, 2013). 
In the oral cavity, SS causes hyposalivation, manifesting as xerostomia, by decreasing 
saliva production from the major salivary glands.  Diminished salivary flow decreases 
patients’ functional ability and increases caries rate (von Bultzingslowen et al., 2007). 
Decreased salivary flow also has a profound negative impact on quality of life and can 
cause social isolation, depression, and lack of personal satisfaction. Control of these 
symptoms can be very challenging (Vivino et al., 2016; C.H. Shiboski et al., 2017).  
The physical symptoms of SS are treated with a variety of medications, ranging from 
topical salivary substitutes to systemic agents. Many patients with primarily oral 
manifestations of SS are managed with cholinergic agents such as pilocarpine or 
cevimeline, both of which have been found to increase the flow of saliva and improve the 
patient experience of oral dryness. In addition, some patients are managed with disease 
modifying antirheumatic drugs (DMARDs) including azathioprine, hydroxychloroquine, 
and cyclosporine. Studies focused on these agents have shown mixed results when 
compared with placebo. Management of SS with non-pharmaceutical therapies has also 
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been investigated, with potential benefit found after use of acupuncture and 
electrostimulation (Al Hamad, Lodi, Porter, Fedele, & Mercadante, 2018). 
A newer and less studied area in SS is the use of immunobiologics for treatment. 
Immunobiologics, or biologic agents, are defined by the National Cancer Institute at the 
United States’ National Institutes of Health as “a substance made from a living organism 
or its products and used in the prevention, diagnosis, or treatment of cancer and other 
diseases. Biologic agents include antibodies, interleukins, and vaccines” (National 
Cancer Institute, 2016). Since the first biologic agent was approved for patient treatment 
in 1998, this category of medications has significantly expanded in use and prevalence. 
A wide variety of agents that target distinct pathways are currently available. 
A developing body of literature has investigated the use of biologic agents in the 
treatment of SS, particularly in patients with severe systemic complications (Sambataro, 
Sambataro, Dal Bosco, & Polosa, 2017). Existing literature has focused on the use of 
rituximab, with a weak recommendation for the use of rituximab to treat sicca symptoms 
and moderate recommendation for use of rituximab to treat systemic disease (Letaief et 
al., 2018; Saraux, 2010; Souza,  Porfirio, Andriolo, Albuquerque, & Trevisani, 2016; 
Verstappen, van Nimwegen, Vissink, Kroese, & Bootsma, 2017). The World Workshop 
on Oral Medicine VII reviewed the literature relating to the use of biologic agents on oral 
signs and symptoms in SS. Existing literature has not been combined into a consensus on 
the use of rituximab for treatment of SS, particularly where oral signs and symptoms are 
concerned. In addition, limited evidence exists on use of other immunobiologics in SS. 
Given these points, we performed a systematic review with two objectives: 1) to 
determine the efficacy of rituximab as compared to placebo treatment for the treatment 
of oral disease related to pSS, as measured through symptomatic improvement and 
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objective change in salivary measures and 2) to determine the evidence available for use 
of other biologic agents to treat the oral component of SS. 
 
2. METHODS 
 
We searched the English language literature for studies and reviews in 
MEDLINE® (via PubMed), Embase, Scopus and the Cochrane Library from date of 
database inception through October 25, 2018 using general terms for biologics, or terms 
for specific drugs or drug classes combined with terms for SS. We used either medical 
subject headings (MeSH) or Embase subject headings (Emtree) where available and 
keywords when applicable. We searched for conference papers in Embase and Scopus 
and unpublished clinical trials using ClinicalTrials.gov and the WHO International 
Clinical Trials Registry Platform. This study was structured according to the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. 
Our literature search initially included case reports, case series, narrative reviews, 
observational studies and randomized clinical trials (RCTs) where full text was available 
and any abstracts that contained sufficient data for analysis. For this systematic review, 
inclusion criteria were restricted to randomized clinical trials and observational studies, 
either in full text or abstract form, that discussed the use of biologic agents in SS and were 
published after January 1, 2002. No restrictions were imposed on the duration of follow 
up.  Exclusion criteria included papers not in English, where the full text was not available 
and the abstract did not contain sufficient information, those that reported on 
interventions other than biologic agents, and papers that did not include sufficient 
information about oral outcomes. 
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Titles and abstracts of all references were screened by two independent reviewers 
(LAG and KF). Any disagreement was resolved through discussion and consensus. Full 
text of all potentially relevant papers was reviewed and screened in duplicate. 
Discordances were resolved through discussion. Ineligible studies were sorted according 
to exclusion criteria. Relevant data from included articles was extracted into a 
standardized form by either LAG or KF and independently verified by the other. 
Information from each included study was then collected including but not limited to 1) 
participants – individuals diagnosed with SS according to American-European consensus 
group (AECG) (Vitali et al., 2002), American College of Rheumatology (ACR) (S.C. 
Shiboski et al., 2012) or ACR/European League Against Rheumatism (EULAR) (C.H. 
Shiboski et al., 2017) or other criteria, demographic details including age, gender, disease 
duration and severity, and indication for treatment with immunobiologics;  2) 
immunobiologic agent prescribed and any additional treatment; 3) dosage, frequency, 
route of administration and number of doses; 4) control; 5) outcome measures; and 6) 
adverse events.  Observational studies were considered when there was no evidence 
available from RCTs on a particular agent. Risk of bias for randomized controlled studies 
was assessed using the Cochrane Collaboration tool and included random sequence 
generation and selection, allocation concealment (selection bias), blinding of participants 
and personnel (performance bias), blinding of outcome assessment in patient-related 
outcomes (detection bias), blinding of outcome assessment for mortality (detection bias), 
incomplete short term (2-6 weeks) outcome data addressed (attrition bias), incomplete 
long-term (>6 weeks) outcome data addressed (attrition bias), and selective reporting 
(reporting bias) (Higgins et al., 2011). Risk of bias from observational studies was 
assessed and is included as supplementary table 1. 
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The primary outcomes in this study were xerostomia and salivary gland function 
as measured by unstimulated and stimulated salivary flow rates. Secondary outcomes 
included: visual analogue scales (VAS) for oral dryness, overall dryness, and global 
measures, the EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) (Seror et 
al., 2010), symptomatic changes evaluated through the EULAR Sjögren’s Syndrome 
Patient Reported Index (ESSPRI) (Seror et al., 2011), and quality of life measures. A 
qualitative synthesis was planned to combine any outcome measures reported 
homogenously across included studies.  
The level of evidence (LoE) was assessed according to the Somerfield Criteria 
(Somerfield et al 2000), which considers and scores the type of evidence from I 
(metanalyses and well-designed RCTs) to V (case reports) and provides a grade for the 
recommendation (ranging from A to D based on the strength of the conclusions).  
 
RESULTS 
 
We included seventeen randomized controlled trials (RCTs) and observational 
studies in this review (Figure 1). Most of the included studies diagnosed subjects 
according to AECG criteria (9 studies) (Vitali et al., 2002). Eleven papers were identified 
that reported on seven different RCTs. Of these, four studied the use of rituximab, while 
one each studied infliximab, etanercept, and the novel agent CFZ533. Six papers reported 
on five observational studies using abatacept, epratuzumab and belimumab. 
Observational studies covering agents evaluated in the included RCTs (11 papers on 
rituximab and 1 paper on etanercept) were not included in this report (Fig. 1a).  
In terms of outcomes, six studies measured xerostomia via a VAS. ESSPRI, which 
includes xerostomia, was examined in two studies. Salivary gland function was assessed 
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using unstimulated salivary flow (n=12 papers) and stimulated salivary flow (n=4 
papers). Studies also assessed objective measures using ESSDAI. Salivary gland 
morphology and volume, measured by ultrasonography, were evaluated in three studies. 
Most studies reported a low rate of side effects, and none reported any side effects specific 
to the oral cavity. There was significant heterogeneity in how xerostomia and salivary 
gland-related outcomes were reported between the studies, preventing a metanalysis from 
being performed. 
Risk of bias for the randomized clinical trial reports is shown in Figure 2. Nine 
of the reports showed both adequate sequence generation and allocation concealment. 
Blinding of treatment was observed in 8 of 11 papers, but outcome assessors were clearly 
blinded in only one paper. Outcome data was complete in 7 of the manuscripts, and 8 of 
11 were free from selective reporting.   
The majority of the included studies investigated the use of anti-B cell agents 
(rituximab: 4 studies, belimumab and epratuzumab: 1 each), followed by anti-tumor 
necrosis factor (TNF) agents (infliximab, etanercept: 1 each), costimulatory signal 
inhibitors (abatacept: 3), and a novel anti CD40 inhibitor (CFZ533: 1). The studies are 
described below and summarized in supplementary tables 2 and 3. 
No deaths secondary to treatment with immunobiologics were reported by any 
included study. Although AEs were commonly observed, they were often mild and self-
limited. Infectious AEs were frequent, but severe infection was rarely observed. Cancer 
was a significant AE reported occurring in six patients (3 cases of breast cancer). Oral 
AEs were rarely reported and included stomatitis (abatacept), aphthous-like lesions 
(belimumab) and dental abscess (epratuzumab).  
 
Anti-B cell agents 
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Rituximab 
Rituximab is a chimeric monoclonal antibody that targets CD20 on the surface of 
B cells and causes apoptosis. Rituximab use in Sjögren’s syndrome was investigated in 
four RCTs and reported in eight manuscripts.  
Dass et al., (2008) completed the first RCT on patients with pSS. Although the 
primary outcomes of this trial were global disease ratings, the authors did evaluate 
unstimulated salivary flow rate before and after treatment. Rituximab did not improve the 
unstimulated salivary flow compared to placebo. This study was found to have a low to 
unclear risk of bias. 
Meijer et al., (2010) evaluated both stimulated and unstimulated salivary flow 
rates, as well as oral dryness via VAS. They found a reduction in oral dryness ratings in 
the rituximab group. Oral dryness during the night showed a sustained response during 
follow up for 48 weeks. Rituximab promoted the improvement of both stimulated and 
unstimulated whole saliva, as well as salivary flow in both the parotid and 
submandibular/sublingual glands. In contrast, patients treated with placebo exhibited a 
reduction in salivary flow over the treatment period. Their study showed a low risk of 
bias in the majority of domains. 
The Tolerance and Efficacy of Rituximab in Primary Sjögren’s Syndrome 
(TEARS) study was reported on multiple times. Devauchelle-Pensec et al., (2014) 
showed that after treatment with rituximab, oral VAS and salivary flow rate did not 
significantly improve. ESSDAI decreased, but this effect was only significant at week 6. 
This report was at low risk of bias. Jousse-Joulin et al. (2015) evaluated ultrasonographic 
findings in these patients and reported a reduction in salivary gland swelling during 
treatment. In this report, both outcome data and reporting measures were found to be at 
high risk of bias. Cornec et al. (2016) also evaluated ultrasonographic findings and 
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reported a decrease in hypoechoic areas in those patients who reported at least a 30% 
improvement in oral dryness (responders). In addition, rituximab responders had higher 
baseline unstimulated whole salivary flow rates (more mild disease) than non-responders. 
In this study, only attrition bias exhibited high risk of bias. Cornec et al. (2017) correlated 
quality of life measures as determined by the Short Form 36 (SF-36) with ratings of SS 
disease activity. They found that patient ESSPRI ratings, measuring subjective 
symptoms, were strongly correlated with SF-36, with significant correlations between 
ESSPRI rating and each individual domain of the SF-36. The ESSDAI ratings did not 
correlate with the overall SF-36 score or with the majority of reported domains. This 
study was showed a low overall risk of bias. 
Finally, the TRial of Anti-B-Cell Therapy In patients with primary SS 
(TRACTISS) study was reported in two publications (Bowman et al., 2017; Fisher et al., 
2018). Bowman et al. (2017) reported no difference between rituximab and placebo in 
the number of patients with at least a 30% reduction in their ratings of fatigue and oral 
dryness. The mean unstimulated salivary flow difference between groups was, however, 
statistically significant. Fisher et al. (2018) evaluated salivary gland ultrasounds at 
baseline and at least once after that. They scored improvement as Total Ultrasound Score 
(TUS), a combined measure of echogenicity, consistency, definition, glands involved, 
and size of hypoechoic foci. TUS reduction at weeks 16 and 48 was significant and stable 
over time. The glandular characteristics displayed statistically significant improvement 
at week 16 and continued improvement at week 48. TUS alteration was not associated 
with ESSDAI or salivary flow rates at any time points.  Both of these studies showed a 
low risk of bias. 
These results show mixed evidence for the use of rituximab in SS, with a 
combined level of evidence of IB (LOE IB). 
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Epratuzumab 
There was one observational study on Epratuzumab. This is a human monoclonal 
antibody that targets the CD22 protein on mature B cells. In their 2006 study, Steinfeld 
and colleagues investigated the use of epratuzumab in pSS (Steinfeld et al., 2006). 
Throughout the study period, successively larger percentages of patients exhibited 
subjective improvement as measured by at least 20% improvement in VAS for dry mouth 
over baseline (LOE IIIB). 
Belimumab 
There was one observational study reported in two papers assessing belimumab’s 
efficacy for treatment of SS. Belimumab is a human monoclonal antibody targeting B-
cell activating factor (BAFF). Mariette et al. (2015) evaluated the efficacy of belimumab 
in pSS. They showed a significant reduction in VAS for dry mouth, ESSDAI, and 
ESSPRI. No change in salivary flow rate was observed.  De Vita et al. (2015) also 
reported on this trial. They noted that those patients responding at week 28 maintained or 
improved their subjective and objective measures at week 52 (LOE: IIIB). 
Anti-TNF 
Infliximab 
 Infliximab is a chimeric anti-TNF agent targeting TNF-𝛂 that was explored in the 
Trial of Remicade in Primary Sjögren’s Syndrome (TRIPSS), an RCT. Mariette et al. 
(2004) published the results in 2004. There was no sustainable response to treatment and 
no significant difference between groups in VAS. There was no significant change in 
focus score or salivary flow rate after treatment. This study was at low risk of bias except 
as related to funding sources (LOE: IIB). 
Etanercept 
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Etanercept is a fusion protein that binds to TNF-𝛂. Sankar et al. (2004) completed an 
RCT to evaluate its efficacy in SS and failed to show evidence of improvement in any 
oral or general outcomes. This trial did show high risk of bias in both attrition and 
reporting and uncertain risk in multiple other domains (LOE IIB).  
 
Costimulatory Signal Inhibitors 
Abatacept 
There were three observational studies assessing abatacept efficacy in SS. Abatacept 
is a fusion protein that targets CD80 and CD86 on T cells, preventing activation. Adler et 
al. (2013) studied the histologic, serologic, and clinical response of 11 pSS patients to 
abatacept. The authors observed a significant increase in saliva secretion, a reduction in 
focus scores on minor salivary gland biopsy, and a decreased density of infiltrating 
lymphocytes within the foci after treatment.  
Meiners et al. (2014) evaluated the efficacy of abatacept in 15 patients with early 
and active pSS. Patients were required to exhibit a stimulated whole salivary flow rate 
higher than 0.1mL/min for inclusion. Median ESSDAI decreased at week 24 but returned 
to baseline by week 48. ESSPRI decreased during treatment and did not rebound. 
Unstimulated salivary flow did not change during or after treatment, while stimulated 
salivary flow was stable during treatment and decreased significantly post-treatment. 
Tsuboi et al. (2016) evaluated the efficacy of abatacept in patients with SS and 
rheumatoid arthritis (sSS) using salivary gland biopsy and salivary flow rate. Patients 
with a less notable minor salivary gland inflammatory infiltrate at baseline exhibited an 
increase in salivary flow rate at week 24.  
These combined results show a trend toward increased salivary flow and improved 
subjective measures after treatment with abatacept (LOE IIIB). 
  13 
Anti-CD40 
CFZ533 
CFZ533 is a potent inhibitor of CD40 stimulation, limiting the formation of 
ectopic germinal centers. Fisher et al. (2017) performed an RCT to evaluate the effect of 
either 3mg/kg or 10mg/kg CFZ533 in 4 doses over 3 weeks for pSS. The higher dose was 
shown to reduce the ESSDAI most effectively. ESSPRI and serum levels of CXCL13 (a 
germinal center-related biomarker) were also reduced (LOE: IIB). This study is currently 
only published in abstract form, leaving most categories at uncertain risk of bias. 
 
3. DISCUSSION 
 
Immunobiologics have been clinically tested and used in the off-label management of SS 
and its systemic complications for more than a decade (Zandbelt et al., 2004). Some 
systematic reviews have assessed the use of these drugs in the management of systemic 
disease in SS (Al Hamad et al., 2018; Souza et al., 2016), but this is the first systematic 
review to assess the efficacy of immunobiologics in the management of oral disease. We 
determined efficacy by considering several outcomes including salivary flow, 
xerostomia, and ultrasonographic pattern of major salivary glands. Eleven randomized 
clinical trials and eighteen observational studies were included, reporting on four classes 
of biologics – anti-B cell (rituximab, epratuzumab, and belimumab), anti-TNF 
(infliximab and etanercept), inhibition of costimulatory signal (abatacept) and anti-CD40 
(CFZ533) therapy. RCTs included 477 patients (253 on biologics) and observational 
studies included 127 patients on biologics. Oral outcomes were clearly described in each 
study. Overall, these studies showed a very low rate of adverse effects, but recognized 
complications from the use of biologic agents should be thoroughly discussed with 
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patients before treatment with these drugs.  Rituximab has been evaluated most 
extensively, allowing for more conclusions on this agent. 
Our results clearly show, based on two RCTs, that infliximab and etanercept are 
ineffective for the management of salivary gland disease in SS (Mariette et al., 2004; 
Sankar et al., 2004). Treatment with these medications produced no difference in oral 
dryness or salivary flow.  
On the other hand, abatacept, an agent that prevents the antigen-presenting cells 
from delivering the costimulatory signal, showed promise in three open-label studies 
(Adler et al., 2013; Meijer et al., 2010; Tsuboi et al., 2016). In these studies, 
improvements to xerostomia and salivary flow rates (both unstimulated and stimulated) 
were observed, as was as a reduction in the inflammatory infiltrate in minor salivary 
glands. Since these studies had an open-label design, however, RCTs are required to 
confirm these findings.  
Anti-B cell treatment has been most commonly used to reduce SS disease activity 
and manage systemic complications. However, studies on rituximab show mixed 
evidence on the agent’s efficacy for treating oral disease in SS. The RCTs studying 
rituximab were mostly at low risk of bias, with some areas of each exhibiting unclear risk 
of bias, and with selected domains at high risk of bias in two studies (Cornec 2016, 
Jousse-Joulin et al. 2015). The TEARS and TRACTISS studies have demonstrated that 
rituximab was able to improve salivary gland echostructure by modifying glandular 
patterns after treatment (Fisher et al., 2018; Jousse-Joulin et al., 2015). On the other hand, 
there are conflicting data regarding its efficacy on xerostomia and salivary flow. Meijer 
et al. (2010) reported benefit from rituximab in the improvement of oral dryness. They 
included patients with residual stimulated salivary flow at baseline, which may be the key 
to a clinically relevant response. As part of the TEARS study, Cornec et al., (2016) 
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evaluated those patients who had salivary gland ultrasound data available at baseline, and 
also reported an improvement of xerostomia. They showed that patients who presented at 
least 30% improvement in oral dryness VAS had fewer salivary gland ultrasound 
alterations at baseline, reinforcing the hypothesis that a measurable salivary gland 
function at baseline is important to clinical response. However, analysis of the entire 
TEARS cohort showed a stable, but nonsignificant reduction in oral dryness after 
rituximab treatment (Devauchelle-Pensec et al., 2014). Bowman et al. (Bowman et al., 
2017) also failed to show changes in oral dryness at any time point in the TRACTISS 
study. Their inclusion of patients with severe glandular disease may have influenced this 
outcome.  
The effect of rituximab on xerostomia was also evaluated in seven observational 
studies, each of which showed a positive effect (Carubbi et al., 2013; Devauchelle-Pensec 
et al., 2011; Devauchelle-Pensec et al., 2007; Galarza et al., 2008; Gottenberg et al., 2005; 
Pijpe et al., 2005; St Clair et al., 2013), although the uncontrolled nature of these studies 
may have influenced the results (Concato, Shah, & Horwitz, 2000). These data also 
showed improvement of parotid gland swelling in small numbers of affected patients 
(Galarza et al., 2008; Gottenberg et al., 2013; Gottenberg et al., 2005). In addition, not all 
studies commented on the timing of treatment or salivary gland function at baseline of 
included subjects, which may explain some variation in the reported results. 
Our results, therefore, suggest that rituximab is effective in improving the salivary 
flow rate in SS. Meijer et al. (2010) and the TRACTISS study (Bowman et al., 2017) each 
reported improvement, while the TEARS study (Devauchelle-Pensec et al., 2014) showed 
no change in flow. However, the TEARS study included patients up to 10 years after 
initial diagnosis, and patients received two doses of rituximab on weeks 0 and 2 post-
enrollment. In contrast, Meijer et al. (2010) evaluated patients with at least some residual 
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saliva (stimulated whole saliva 0.15 ml/minute). The TRACTISS study was primarily 
designed to evaluate the effect of rituximab on oral dryness and four doses were 
administered at weeks 0, 2, 24, and 26 post-enrollment. These additional doses, along 
with a measurable baseline salivary flow, may be responsible for the sustained 
improvement.  
Other anti-B cell therapies have also shown some benefit in the management of 
oral disease in SS. Preliminary results on the use of belimumab from one uncontrolled 
trial suggest some efficacy as measured by xerostomia, parotid gland swelling, and 
ESSDAI. The results were particularly promising for the glandular domain of this scale. 
However, no effect on salivary flow was observed (De Vita et al., 2015; Mariette et al., 
2015).  
Epratuzumab is an anti-CD22 drug that causes less B cell depletion than 
rituximab, and its use in SS patients showed a clinically significant improvement of 
salivary flow in more than 60% of the patients studied in one observational trial (Steinfeld 
et al., 2006). 
Recently, a new intervention was proposed to treat SS. CFZ533, a drug that 
selectively blocks CD40 costimulation and reduces germinal center formation, was tested 
in an RCT in 3mg/kg and 10mg/kg doses. This trial showed that the drug was safe and 
well tolerated, and the higher dose was more effective in reducing ESSDAI and ESSPRI 
(Fisher et al., 2017). 
In summary, the use of biologics in SS represents a new frontier in the 
management of this disease. Anti-B cell therapies are the leaders of immunobiologics for 
treatment of SS. Here, we show that rituximab has the most evidence in the treatment of 
xerostomia and stimulation of salivary flow improvement in SS, especially with 
continuous treatment. Abatacept, belimumab, epratuzumab, and CFZ533 are promising 
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alternatives, and additional head-to-head RCTs may clarify their benefit and define cost-
effectiveness.  
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Figure Legends 
 
Figure 1. Flow chart of study selection according to the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) standard. 
 
Figure 2. Risk of bias evaluation of randomized clinical trials according to Cochrane 
Collaboration risk of bias tool. 
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Table 1. Summary of efficacy of the immunobiologics in the management of salivary 
gland disease of Sjögren’s syndrome. 
 
Category of 
agent 
Medication 
Type of 
study 
Summary of evidence LoE 
Anti-B cell 
  
Rituximab RCTs 
Improvement of unstimulated 
salivary flow rate, effect on 
xerostomia not demonstrated.  
Significant improvement in 
glandular parenchyma in two 
studies. 
IB 
Epratuzumab 
Single group 
open trial 
Improvement in unstimulated flow 
(36% of patients at week 18 and in 
64% of patients at week 32). 
IIIB 
Belimumab 
Single group 
open trial 
Reduction in VAS dryness, ESSPRI 
and ESSDAI, with evidence of 
sustained response (52 weeks). No 
improvement in salivary gland 
function. Reduction in non-
malignant salivary gland swelling.  
IIIB 
Anti TNF-𝛂   
Infliximab RCT 
No difference in salivary flow rates 
or xerostomia. No changes in 
microscopic aspects of minor 
salivary glands.  
IIB 
Etanercept RCT 
No difference in VAS dryness. No 
improvement in salivary gland 
function. 
IIB 
Costimulator
y Signal 
Inhibitors 
Abatacept 
Single group 
open label 
trials 
Two of three papers 
demonstrated improvement in 
salivary gland function. Reduction 
of ESSPRI and ESSDAI was 
observed until 24 weeks but not 
after 48 weeks. Improvement of 
xerostomia was noted. 
IIIB 
Anti-CD40 CFZ533 RCT 
ESSPRI and ESSDAI improved with 
the higher dose (10mg/kg). 
IIB 
 
 
 

